MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MannKind Corporation

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcutis Biotherapeutics (ARQT) and MannKind (MNKD) w...

Wall Street Analysts Are Bullish on Top Healthcare Picks

MannKind ( ($MNKD) ) has issued an announcement. On May 29, 2026, MannKind announced that the U.S. Food and Drug Administration approved Afrezza (i...

MannKind Gains FDA Approval for Afrezza Pediatric Use

In a report released on May 29, Benjamin Burnett from Wells Fargo maintained a Buy rating on MannKind, with a price target of $11.00. The company’s...

Wells Fargo Sticks to Its Buy Rating for MannKind (MNKD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on MannKind (MNKD), Biohaven Ltd. (BHVN) and Precisio...

Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)

The latest update is out from MannKind ( ($MNKD) ). At MannKind’s 2026 Annual Meeting of Stockholders held on May 20, 2026, shareholders elected al...

Market Cap	$1.77B	P/E Ratio	N/A
52W High	$6.51	52W Low	$2.23
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	27.2%	52W Position	40.0%
Overall Score	46	Value Score	20
Quality Score	36	Technical Score	83

EPS Current Est	$-0.06	EPS Next Est	$0.12
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MNKD	$3.94	+0.51%	16.62M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MNKD	$3.94	+0.5%	16.62M
3
4
5
6

MNKD

MNKD

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get MannKind Corporation Data in Excel

Get MannKind Corporation Data in Excel